Evidence map›Paper›PMID 21127062›Full record

ArticleThe Journal of biological chemistry2011

Azadirachtin interacts with retinoic acid receptors and inhibits retinoic acid-mediated biological responses.

Maikho Thoh, Banaganapalli Babajan, Pongali B Raghavendra, Chitta Sureshkumar, Sunil K Manna

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Azadirachta indica mitigates behavioral impairments, oxidative damage, histological alterations and apoptosis in focal cerebral ischemia-reperfusion model of rats.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maikho ThohLaboratory of Immunology, Centre for DNA Fingerprinting and Diagnostics, Nampally, Hyderabad 500001, India.
Banaganapalli Babajan
Pongali B Raghavendra
Chitta Sureshkumar
Sunil K Manna
Centre for DNA Fingerprinting and Diagnostics · INSri Krishnadevaraya University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Considering the role of retinoids in regulation of more than 500 genes involved in cell cycle and growth arrest, a detailed understanding of the mechanism and its regulation is useful for therapy. The extract of the medicinal plant Neem (Azadirachta indica) is used against several ailments especially for anti-inflammatory, anti-itching, spermicidal, anticancer, and insecticidal activities. In this report we prove the detailed mechanism on the regulation of retinoic acid-mediated cell signaling by azadirachtin, active components of neem extract. Azadirachtin repressed all trans-retinoic acid (ATRA)-mediated nuclear transcription factor κB (NF-κB) activation, not the DNA binding but the NF-κB-dependent gene expression. It did not inhibit IκBα degradation, IκBα kinase activity, or p65 phosphorylation and its nuclear translocation but inhibited NF-κB-dependent reporter gene expression. Azadirachtin inhibited TRAF6-mediated, but not TRAF2-mediated NF-κB activation. It inhibited ATRA-induced Sp1 and CREB (cAMP-response element-binding protein) DNA binding. Azadirachtin inhibited ATRA binding with retinoid receptors, which is supported by biochemical and in silico evidences. Azadirachtin showed strong interaction with retinoid receptors. It suppressed ATRA-mediated removal of retinoid receptors, bound with DNA by inhibiting ATRA binding to its receptors. Overall, our data suggest that azadirachtin interacts with retinoic acid receptors and suppresses ATRA binding, inhibits falling off the receptors, and activates transcription factors like CREB, Sp1, NF-κB, etc. Thus, azadirachtin exerts anti-inflammatory and anti-metastatic responses by a novel pathway that would be beneficial for further anti-inflammatory and anti-cancer therapies.

Indexed as

Active Transport, Cell NucleusAnti-Inflammatory AgentsAntineoplastic AgentsAzadirachtaCell NucleusCyclic AMP Response Element-Binding ProteinHumansI-kappa B ProteinsInsecticidesLimoninsNF-KappaB Inhibitor alphaPhosphorylationReceptors, Retinoic AcidSp1 Transcription FactorTNF Receptor-Associated Factor 2TNF Receptor-Associated Factor 6Anti-Inflammatory AgentsAntineoplastic AgentsazadirachtinCREB1 protein, humanCyclic AMP Response Element-Binding ProteinI-kappa B ProteinsInsecticidesLimoninsNF-KappaB Inhibitor alphaNFKBIA protein, humanReceptors, Retinoic AcidRELA protein, humanSp1 Transcription FactorTNF Receptor-Associated Factor 2TNF Receptor-Associated Factor 6Transcription Factor RelATretinoin

Identifiers

PMID21127062
PMCPMC3039373
OpenAlexW2045848405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.